Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the treatment of all types of liver cancer to progress into the clinical stage.

Related Keywords

Singapore ,China ,Hannover ,Niedersachsen ,Germany ,Australia ,Guangzhou ,Guangdong ,France ,Chinese , ,Sun Yat Sen University Cancer Center ,Hannover Medical School ,Fudan University Shanghai Cancer Center ,Drug Administration ,Orphan Drug Designation ,Fast Track Designation ,Liver Cancer ,Malignant Tumor ,Slymphocytes ,Oil Therapy ,Clinical Trial ,Gene Therapy ,